Drugs / ADGRE2 CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05463640 | Aug 2022 → Aug 2024 | acute myeloid leukemia | Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADGRE2 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05463640 ↗ |
| Modality | Cell therapy | “CAR-T cells therapy” NCT05463640 ↗ |